Clinical Trial Update: Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab. [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating multimodal imaging biomarkers to predict anatomical outcomes in naive patients with neovascular age-related macular degeneration…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• BEOVU (BROLUCIZUMAB)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neovascular Age-related Macular Degeneration | Phase 4 | Status: COMPLETED | Results posted: 2025-02-24